Induction of robust humoral immunity against <scp>SARS‐CoV</scp>‐2 after vaccine administration in previously infected haematological cancer patients

Borgogna, Cinzia; Bruna, Riccardo; Griffante, Gloria; Martuscelli, Licia; Andrea, Marco De; Ferrante, Daniela; Patriarca, Andrea; Mahmoud, Abdurraouf Mokhtar; Ucciero, Maghalie Anais Marie; Gaidano, Valentina; Marchetti, Monia; Rapezzi, Davide; Lai, Michele; Pistello, Mauro; Ladetto, Marco; Massaia, Massimo; Gaïdano, Gianluca; Gariglio, Marisa

doi:10.1111/bjh.18429

Cited by 5 publications

(9 citation statements)

References 16 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple studies, including our own previous work, have reported improved vaccination responses following natural SARS‐CoV‐2 infection, both in terms of anti‐SARS‐CoV‐2 IgG levels and antibody neutralizing activities 16,31,32 . Magicova et al, 32 observed a marked difference in seroconversion rates between KTRs with prior SARS‐CoV‐2 infection and those without.…”

Section: Discussionmentioning

confidence: 91%

“…However, KTRs experiencing SARS-CoV-2 breakthrough infections did not exhibit low eGFR rates, as these were within a normal range (median: 36. both in terms of anti-SARS-CoV-2 IgG levels and antibody neutralizing activities. 16,31,32 Magicova et al, 32 While this study did not assess T cell-mediated immunity, its strength lies in the longitudinal analysis of both anti-s IgG titers and the neutralizing activity at multiple time points over a 1-year observation period. This comprehensive approach, to our knowledge, is unprecedented in KTR research.…”

Section: Seroconversion Rate and Magnitude Of The Igg And Neutralizin...mentioning

confidence: 99%

See 1 more Smart Citation

A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS‐CoV‐2 mRNA vaccine

Borgogna,

Ferrante,

Rosso

et al. 2024

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Kidney transplant recipients (KTRs), like other solid organ transplant recipients display a suboptimal response to mRNA vaccines, with only about half achieving seroconversion after two doses. However, the effectiveness of a booster dose, particularly in generating neutralizing antibodies (NAbs), remains poorly understood, as most studies have mainly focused on non‐neutralizing antibodies. Here, we have longitudinally assessed the humoral response to the SARS‐CoV‐2 mRNA vaccine in 40 KTRs over a year, examining changes in both anti‐spike IgG and NAbs following a booster dose administered about 5 months post‐second dose. We found a significant humoral response increase 5 months post‐booster, a stark contrast to the attenuated response observed after the second dose. Of note, nearly a quarter of participants did not achieve protective plasma levels even after the booster dose. We also found that the higher estimated glomerular filtration rate (eGFR) correlated with a more robust humoral response postvaccination. Altogether, these findings underscore the effectiveness of the booster dose in enhancing durable humoral immunity in KTRs, as evidenced by the protective level of NAbs found in 65% of the patients 5 months post‐ booster, especially those with higher eGFR rates.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Seroconversion Rate and Magnitude Of The Igg And Neutralizin...mentioning

confidence: 99%

A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS‐CoV‐2 mRNA vaccine

Borgogna,

Ferrante,

Rosso

et al. 2024

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Based on this biobank initiative, disease-specific biobanking studies have already been published ( Table 1 ) [ 34 , 35 , 36 , 37 , 38 , 39 , 40 ], and all the invited patients participating in these studies also adhered to the broader aims of the biobank by providing specific consent.…”

Section: Resultsmentioning

confidence: 99%

“…UPO Biobank also adopts strategies to enhance and maintain the quality of the biological samples, starting from their handling to their final preservation, as well as to ensure data protection. Toward this aim, UPO Biobank runs a quality management system that is in agreement with national and international indications [ 34 ]. In particular, the quality management system of a biobank contains documented quality control policies and written standard operating procedures underlying the collection, manipulation, aliquotation, preservation, and distribution of biological material and associated data [ 49 , 50 , 51 ].…”

Section: Resultsmentioning

confidence: 99%

UPO Biobank: The Challenge of Integrating Biobanking into the Academic Environment to Support Translational Research

Bettio,

Mazzucco,

Aleni

et al. 2023

JPM

Self Cite

View full text Add to dashboard Cite

Biobanks are driving motors of precision and personalized medicine by providing high-quality biological material/data through the standardization and harmonization of their collection, preservation, and distribution. UPO Biobank was established in 2020 as an institutional, disease, and population biobank within the University of Piemonte Orientale (UPO) for the promotion and support of high-quality, multidisciplinary studies. UPO Biobank collaborates with UPO researchers, sustaining academic translational research, and supports the Novara Cohort Study, a longitudinal cohort study involving the population in the Novara area that will collect data and biological specimens that will be available for epidemiological, public health, and biological studies on aging. UPO Biobank has been developed by implementing the quality standards for the field and the ethical and legal issues and normative about privacy protection, data collection, and sharing. As a member of the “Biobanking and Biomolecular Resources Research Infrastructure” (BBMRI) network, UPO Biobank aims to expand its activity worldwide and launch cooperation with new national and international partners and researchers. The objective of this manuscript is to report an institutional and operational experience through the description of the technical and procedural solutions and ethical and scientific implications associated with the establishment of this university research biobank.

show abstract

“…Antigen-presenting cells (such as dendritic cells) take up and process these tumor antigens before presenting them to T cells and inducing an immune response to the tumor antigen. Mannose-modified nanoparticles modulate immunosuppressive factors in the tumor microenvironment, thereby reducing T cell suppression [191][192][193][194][195]. In the tumor microenvironment, the presence of immunosuppressive factors (such as PD-L1, TGF-β, etc.)…”

Section: Activation Of T Cells By Mannose Modified Lipid Calcium Phos...mentioning

confidence: 99%

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

Wu,

Qian,

et al. 2024

Preprint

View full text Add to dashboard Cite

With the rapid development of tumor immunotherapy, nanoparticle vaccines have attracted much attention as a potential therapeutic strategy. The potential role of the mannose-modified lipid calcium phosphate nanoparticle vaccine in enhancing the anti-tumor immune response was investigated. The aim of this study was to investigate the effect of mannose modification on the immune response of nanoparticles in regulating the tumor microenvironment through systematic review and analysis and to explore its potential clinical application in tumor therapy. Currently, despite the potential advantages of nanoparticle vaccines in immunotherapy, achieving an effective immune response in the tumor microenvironment remains a challenge. Tumor immune escape and overexpression of immunosuppressive factors limit its clinical application. Therefore, this study will explore how to intervene in the immunosuppressive mechanism in the tumor microenvironment through mannose-modified lipid calcium phosphate nanoparticle vaccines so as to improve the immunotherapy effect of tumor patients and provide new ideas and strategies for the field of tumor therapy.

show abstract

Induction of robust humoral immunity against SARS‐CoV‐2 after vaccine administration in previously infected haematological cancer patients

Cited by 5 publications

References 16 publications

A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS‐CoV‐2 mRNA vaccine

A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS‐CoV‐2 mRNA vaccine

UPO Biobank: The Challenge of Integrating Biobanking into the Academic Environment to Support Translational Research

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

Contact Info

Product

Resources

About